Introduction
============

The insufficient reporting of medical research is a long-lasting and potentially serious universal problem that is not evident to many researchers ([@B1]). All scientific study must be fully and precisely reported, letting a proper understanding of their methodology, findings, and repetition of the same if needed ([@B2], [@B3]). However, some of the reports are far from those standards ([@B2]). Therefore, many instructions that seek to standardize and progress the reporting quality of different kinds of study were established in the past few years ([@B4]).

Strengthening the Reporting of Observational studies in Epidemiology (STROBE) is an instruction whose recommendations have been presented for the purpose of sufficiently report observational studies (cohort, case-control, and cross-sectional studies) ([@B3],[@B5]). STROBE recommendations evaluate the quality of reporting, but not the methodological quality ([@B6]). Furthermore, an insufficient reporting of cross-sectional studies could make possible mistakes in the synthesis and acceptance of new evidence and cause inaccuracies in the validation and the creation of public policies ([@B2]), particularly in areas with inadequate sources like Iran. For example, the prevalence of Congenital Anomaly (CA) is relevant to public health subjects because it had been related to the main causes of disability and mortality among children in developing countries ([@B7], [@B8]).

CA is the main cause of infant mortality; therefore, 21% of mortality during infancy results from these anomalies ([@B9]). This type of anomalies is the fifth leading reason for diminished natural life before the age of 65 and is one of the main causes of disabilities ([@B10], [@B11]). Costs of hospitalization and treatment events for these children carry out a large extra burden on the health system and their families. On the other hand, the diversity of the methods used for diagnosing anomalies and different characteristics of studied populations (live or dead babies) ([@B12]--[@B14]) related to the inadequate reporting in cross-sectional studies; create mistake when interpreting the actual scope of the problem. For that reason, this study aimed to appraise the reporting quality of cross-sectional studies on the subject of the prevalence of CA in Iranian infants, by the STROBE recommendations as an objective tool.

Materials and Methods
=====================

This descriptive study was done in two stages. First, a systematic literature search was carried out to recognize the articles to be taken in the study. Then, the quality of the studies was evaluated with STROBE. This study keeps the recommendations of the PRISMA statement for its reporting ([@B15]).

Data sources and search strategy
--------------------------------

MEDLINE/PubMed and Scopus were searched for published cross-sectional studies. Search keywords were "Congenital anomaly", "birth defect", "prevalence", and "Iran." Persian databases (SID, Iranmedex, MagIran, Elmnet, and Iran Doc) and Google Scholar were also searched using equivalent keywords from 2007 until Dec 2017. In addition, reference section of relevant studies was manually checked to identify further studies missed by the electronic search. Authors were contacted for additional missing data. This study was performed independently and simultaneously by three researchers (MI, MHB, and TKH) and a list of found objects was made. Then, search results were assessed, and no differences in the outcome were obtained between the three authors.

Study selection
---------------

Full-text articles were assessed by three researchers (MI, MHB, and TKH) and those who met the inclusion criteria were selected. Moreover, a secondary search through the bibliographic references of the chosen articles was done, and duplicates were removed. The inclusion criteria included descriptive and cross-sectional studies on the prevalence of congenital the anomalies among infants in Iran; studies were in English and Persian. The exclusion criteria included those studies that mentioned before publishing STROBE's statement (Since 2007, STROBE's statement has been published); studies that investigated the prevalence of congenital anomalies in the animal; qualitative studies, studies presented in conferences; and interventional studies. Short communications, editorials or reviews were excluded.

Instrument
----------

We worked the STROBE items for assessing the quality of the reports. STROBE offers 32 items for the suitable reporting of observational studies. These suggestions express the appropriate method of reporting the title, abstract, introduction, methods, results, discussion, and financing section ([@B5]). Based on the language of each reporting, we used the cross-sectional studies suggested-version, available in Persian or English ([@B3]). For this study, we operated 28 of the 32 recommendations from cross-sectional studies. We considered as not-applicable the items 16b (continuous variables were not categorized), 16c (the objectives of the studies were not to calculate the report of relative or absolute risk), 12d (sampling strategy was single-stage) and 13b (participation in study does not have multistage stage).

Data extraction
---------------

Two methods were used to extract data. The first included information on the general characteristics of each article: first author, name of the study from which the data came from, publication year and language, city, study period, sample size and type of population. The second method is a list of 28 of 32 STROBE items. Three investigators (MI, MHB, and TKH) appraised the full-text of the articles, and the data was extracted. Each researcher considered whether the reports identified met or not the STROBE items. Lastly, the corresponding author of each included article was emailed. In each email, we gave the purpose of the study and the items completed by the article, according to our analysis based on STROBE. This step was performed with the purpose of clarifying potential contrasts with our appraisal. The responses of each author were evaluated based on the methodology expressed above and revisions to our analysis were done as accurate. If no response, a reminder email has been sent 8 d after the first one. We waited for 15 d for the authors to reply, and then our analysis was performed as the ending result.

Analysis
--------

Two kinds of scores were described including score per article and per item. The score per article was described as the number of the STROBE items sufficiently reported, divided by the total of items applicable per article and stated as a percentage. The score per item was described as the number of articles that met each STROBE item, divided by the total of articles for which the item was applicable and stated as a percentage.

Results
=======

We obtained 3328 articles within the database search. From these articles, 2548 were excluded for being duplicates and 754 were excluded for screen by title and abstract and the remaining 35 were checked in full-text. Of these, 18 were rejected because they did not meet the selection criteria, as a result, 17 articles were obtained for extracting information ([@B16]--[@B32]) ([Fig. 1](#F1){ref-type="fig"}).
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General structures of the reports
---------------------------------

[Table 1](#T1){ref-type="table"} summarizes the main structures of the 17 included articles. Most Publication year of articles related to 2013 (23.5%) and 2014 (18%). Of the total, 5 articles (30%, n=4/17) ([@B16], [@B19], [@B23], [@B27],[@B31]) were published in in MEDLINE/PubMed, 4 articles (23.5%, n=4/17) ([@B17], [@B21], [@B25], [@B32]) in Scopus, one article (6%, n=1/17) ([@B30]) in ISI databases and the others (35%, n=7/17) in Persian databases (SID, Elm net, Magiran, Irandoc, Iranmedex) ([@B18], [@B20], [@B22], [@B24], [@B26], [@B28], [@B29]). Only one article (6%, n=1/17) ([@B20]) had used a statistician in the Author List. Mean±SD of the period of reviewing articles was 6±5.3 months and the maximum period was 26 months ([@B24]), and the minimum was 1.5 months ([@B18]). These studies were done between 2000 and 2014 and included 189113 participants from different Iranian cities, involving urban and rural population. According to the publication language, six articles (35.3%) were published in English and 11 articles (64.7%) in Persian.

###### 

Main structures of the articles about the prevalence of congenital anomaly in Iran

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ***Authors name***               ***Publication year***   ***Publication language***   ***Study period***          ***City***     ***Population***   ***age***                                       ***Sample Size***
  -------------------------------- ------------------------ ---------------------------- --------------------------- -------------- ------------------ ----------------------------------------------- -------------------
  Mashhadi et al ([@B16])          2014                     English                      2004--2012                  Tabriz         rural              Children(live birth) under eight years of age   22500

  Mohammadzadeh et al ([@B17])     2013                     Persian                      2007--2008                  Babol          Urban, rural       Newborn(live birth                              1684

  Khoshhal-Rahdar et al ([@B18])   2014                     Persian                      2013--2014                  Dezful         Urban, rural       Newborn(live birth                              4235

  Karbasi et al ([@B19])           2009                     English                      October 2003 to June 2004   Babol          Urban, rural       Newborn(live birth and stillbirth)              4800

  Akbarzadeh et al ([@B20])        2008                     Persian                      2006--2007                  Sabzevar       Urban, rural       Newborn(live birth                              7786

  Alijahan et al ([@B21])          2013                     Persian                      2010--2011                  Ardabil        Urban, rural       Newborn(live birth                              6868

  Hosseini et al ([@B22])          2014                     Persian                      2012                        Sistan         Urban, rural       Newborn(live birth                              1800

  Ahmadzadeh et al ([@B23])        2008                     English                      2003--2006                  Ahwaz          Urban, rural       Newborn(live birth                              4660

  Masoodpoor et al ([@B24])        2013                     Persian                      2007--2008                  Rafsanjan      Urban, rural       Newborn(live birth                              6089

  Tayebi et al ([@B25])            2016                     English                      2008                        Yazd           Urban, rural       Newborn                                         1195

  Kavianyn et al ([@B26])          2016                     Persian                      2008--2011                  Golestan       Urban, rural       Newborn(live birth                              92420

  Jalali et al ([@B27])            2011                     Persian                      2011                        Rasht          Urban, rural       Newborn(live birth                              1824

  Sarrafan et al ([@B28])          2011                     Persian                      2006--2007                  Ahvaz          Urban, rural       Newborn(live birth                              5087

  Amini Nasab et al ([@B29])       2014                     Persian                      2007--2011                  Birjand        Urban              Newborn(live birth                              22076

  Dastgiri et al ([@B30])          2007                     English                      2000--2004                  Tabriz         Urban, rural       Newborn                                         1574

  Rostamizadeh et al ([@B31])      2017                     English                      2002--2003\                 Azarshahr      Urban, rural       Newborn                                         4515
                                                                                         2012--2013                                                                                                    

  Gheshmi et al ([@B32])           2012                     Persian                      2007                        Bandar Abbas   Urban, rural       Newborn(live birth                              7007
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Reporting Quality based on the STROBE items
-------------------------------------------

Eleven (56%) out of the 17 corresponding authors answered, mentioning and supporting if they approved (5/11) or opposed (6/11) with our analysis. Most of the conflicts were found in the items associated with the statistical analysis (the analysis of sensitivity, subgroups and missing data). According to these conflicts, each item was assessed again, and answers were emailed with the respective revisions. [Table 2](#T2){ref-type="table"} shows the number of articles that met each STROBE item. The results of 17 selected articles on the prevalence of CA showed that the overall accordance of the cross-sectional study reports with STROBE items was about 63%. The highest score of those articles was 85% ([@B21]) and the least score was 42% ([@B28]). The most common weakness in the reporting quality was related to methodology and results estimated to be about 54% and 52%, respectively. The items that were fully met were those related to the reporting of the reasons and rationale for the investigation (item 2), to the reporting of the objectives (item 3), to the reporting of the setting (item 5), to provide summary measures (item 15) and summary key results (item 18). On the other hand, the items not reported were those associated with explaining the analysis of the missing data (item 12c), to consider the use of a flowchart for the participants (item 13c) and to indicate the number of participants with missing data for each variable (item 14b). The items with the lowest scores were those associated with the description of the sensitivity analysis (item 12e; 1/13 \[6%\]), to specify the steps taken to identify possible sources of bias (item 9; 1/17 \[6%\]) and to give the sources of funding (item 22; 7/17 \[41%\]).

###### 

Number of articles that fulfill each item of the STROBE Statement

  ***Section***            ***Subsection***            ***Code***   ***item***                                                                                                                                                                                                   ***Fulfill each STROBE**item n%***
  ------------------------ --------------------------- ------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------
                                                       1a           Indicate the study's design with a commonly used term in the title or the abstract                                                                                                                           14 (82)
  **Title and abstract**   Title and abstract          1b           Provide in the abstract an informative and balanced summary of what was found                                                                                                                                16(94)
                           Background/rationale        2            Explain the scientific background and rationale for the investigation being reported                                                                                                                         17 (100)
  **Introduction**         Objectives                  3            State-specific objectives, including any prespecified hypotheses                                                                                                                                             17 (100)
                           Study design                4            Present key elements of study design early in the paper                                                                                                                                                      13(76)
                           Setting                     5            Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection.                                                                             17 (100)
                           Participants                6            Cross-sectional study: give the eligibility criteria and the sources and methods of selection of participants.                                                                                               15(85)
                           Variables                   7            Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.                                                                    15(88)
  **Methods**              Data sources/ measurement   8            For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group.                        16(94)
                           Bias                        9            Describe any efforts to address potential sources of bias.                                                                                                                                                   1(6)
                           Study size                  10           Explain how the study size was arrived at                                                                                                                                                                    13(76)
                           Quantitative variables      11           Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why.                                                                                11(56)
                           Statistical methods         12a          Describe all statistical methods, including those used to control for confounding.                                                                                                                           10(60)
                                                       12b          Describe any methods used to examine subgroups and interactions.                                                                                                                                             1(6)
                                                       12c          Explain how missing data was addressed.                                                                                                                                                                      0(0)
                                                       12d          Cross-sectional study: If applicable, describe analytical methods taking account of sampling strategy                                                                                                        NA
                                                       12e          Describe any sensitivity analyses.                                                                                                                                                                           1(6)
                           Participants                13a          Report numbers of individuals at each stage of study---e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed            16(94)
                                                       13b          Give reasons for non-participation at each stage.                                                                                                                                                            NA
  **Results**                                          13c          Consider use of a flow diagram.                                                                                                                                                                              0(0)
                           Descriptive data            14a          Give characteristics of study participants (e.g. Demographic, clinical, social) and information on exposures and potential confounders.                                                                      15(85)
                                                       14b          Indicate a number of participants with missing data for each variable of interest.                                                                                                                           0(0)
                           Outcome data                15           Cross-sectional study: report numbers of outcome events or summary measures.                                                                                                                                 17(100)
                           Main results                16a          Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g. 95% confidence interval). Make clear which confounders were adjusted for and why they were included.   16(94)
                                                       16b          Report category boundaries when continuous variables were categorized.                                                                                                                                       NA
                                                       16c          If relevant, consider translating estimates of relative risk into absolute risk for a meaningful period.                                                                                                     NA
                           Other Analyses              17           Report other analyses were done -- e.g. Analyses of subgroups and interactions, and sensitivity analyses.                                                                                                    15(85)
                           Key results                 18           Summarize key results with reference to study objectives.                                                                                                                                                    17 (100)
  **Discussion**           Limitations                 19           Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.                                                  9(53)
                           Interpretation              20           Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.                                  15(85)
                           Generalizability            21           Discuss the generalizability (external validity) of the study results.                                                                                                                                       8(46)
  **Other information**    Funding                     22           Give the sources of funding and the role of the funders for the present study and, if applicable, for the original study on which present article is based.                                                  7(41)

Discussion
==========

The results of this study indicated that the performance of the STROBE items for the reporting of cross-sectional studies on the prevalence of CA was inadequate, the median STROBE score being 63%. Reporting rates were lowest for the methodology and results. These insufficiencies are mainly important for methodologically properly organized studies and correctly analyzed. For that purpose, every precise report, to be reliable, need to afford a strong, complete and obvious showing of what was designed, done and found, that simplify the sufficient understanding and publication of their results ([@B3]). Of the 17 articles including 189113 participants, all of them indicated limitations when reporting the methodology associated with the statistical analysis, involving sensitivity analysis, missing data, and sources of bias. Furthermore, the report of the results was not perfect about the explanation of the participant's flow and participants with missing data for each variable.

The some studies evaluating the quality of observational study reporting, with the STROBE statement as a reference, identified a number of deficiencies harmonious with our results, involving marked insufficiencies in reporting the methodology and results ([@B33]--[@B38]), such as inadequate reporting in the management of missing data ([@B35],[@B36],[@B39],[@B40]) and sources of bias ([@B35],[@B40]). Preparing an ideal study report is the main responsibility of the authors, but several methods (editorial board and policies, external reviewers) play an important role in the publication process and also intention to a suitable report ([@B41]). To make this objective, the medical journal must follow reporting guidelines such as recommendations as an editorial policy; besides, reviewers and editors must be trained to its right usage ([@B2]). In general, the quality of reporting of cross-sectional studies could be enhanced if journals present an active policy of compliance with reporting recommendations such as STROBE ([@B42], [@B43]).

The academic reports make a greater purpose besides the production of new knowledge. Specifically, epidemiological researches have diverse attention, usages, and implications. For a more technical spectator, studies should report detailed estimates of the burden of the diseases that let ranking of public policies. Contrariwise, in case of more general spectators, they should offer a consistent implication about a particular condition. On both stages, technical and general spectators, we found that the articles analyzed about CA in Iran have significant restrictions in its report that reduce the suitable application of their findings.

The limitations of our study are that some of our findings might have been different if they were evaluated by other investigators; however, to prevent subjective decisions, each corresponding author was emailed to confirm our analysis, obtaining a rate response (56%). Additionally, we operated a global score for every article to provide a measure of whole reporting. In selecting this system, we do not suggest that all recommendations are of equal significance. On the other hand, we decided to use these policy help readers have an overall view of the quality of the reports and adherence to the STROBE statement in future studies has the potential to improve study reporting, help the appraisal and analysis of CA by reviewers, readers and journal editors, and finally support the practice of evidence-based medicine.

Conclusion
==========

Cross-sectional studies about the prevalence of CA in Iranian infants have an insufficient reporting of important parts such as methods and results. This finding indication a strong need to enhance the reporting quality of such studies to make its role to sufficiently inform relevant subjects for the putting into practice of public health policies.
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